1. Home
  2. WIMI vs CMMB Comparison

WIMI vs CMMB Comparison

Compare WIMI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WiMi Hologram Cloud Inc.

WIMI

WiMi Hologram Cloud Inc.

BUY

Current Price

$0.61

Market Cap

9.3M

Sector

Technology

ML Signal

BUY

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.08

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIMI
CMMB
Founded
2015
2004
Country
China
Israel
Employees
N/A
12
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
8.4M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
WIMI
CMMB
Price
$0.61
$1.08
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $15.00
AVG Volume (30 Days)
★ 156.4K
105.9K
Earning Date
12-18-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 101.67
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
$211.95
N/A
Revenue Next Year
$7.11
N/A
P/E Ratio
★ $1.24
$29.38
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.05
52 Week High
$4.16
$3.44

Technical Indicators

Market Signals
Indicator
WIMI
CMMB
Relative Strength Index (RSI) 32.27 25.00
Support Level N/A $1.05
Resistance Level $1.43 $1.89
Average True Range (ATR) 0.06 0.11
MACD 0.01 -0.00
Stochastic Oscillator 44.35 10.72

Price Performance

Historical Comparison
WIMI
CMMB

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: